Cognition Therapeutics, Inc. Common Stock
CGTXCognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease. The company's approach involves targeting molecular pathways involved in neurodegeneration to develop disease-modifying treatments. Founded with a focus on translating scientific discoveries into innovative medicines, Cognition Therapeutics aims to address unmet medical needs in cognitive disorders.
Company News
Mesoblast Limited has appointed James M. O'Brien as its US-based Chief Financial Officer to support the company's transition to a fully integrated commercial organization, leveraging his extensive financial management experience in life sciences and biotechnology.
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable i...
Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
